Skip to main content
Karen Rodriguez Lorenc on Muck Rack

Karen Rodriguez Lorenc

As seen in: Nature, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Karen Rodriguez

Contact Karen Rodriguez, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

|
By Shaji Kumar Verified, Katja Weisel, Paul Spin, Nicolle A. Bonar, Muhaimen Siddiqui, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael West, Christian Hampp, Jeannette Green, James Harnett, Olivier Humblet, Alexander Breskin, Wenzhen Ge, Jessica J. Jalbert, Rachel Sobel, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Sundar Jagannath
| Nature Verified
Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥3 prior lines of therapy (3L+), or triple-class refractory (TCR).
Open in Who Shared Issue with article?

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

|
By Shaji Kumar Verified, Sundar Jagannath, Katja Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David Siegel, Jorge Monge, Juan Du, Pedro Asensi Cantó, Jae Lee, Maria-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle A. Bonar, Paul Spin, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael West, Christian Hampp, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel Sobel, Jessica J. Jalbert, Karen Rodriguez Lorenc, Qiufei Ma, Brian Durie, Javier de la Rubia, Muhaimen Siddiqui, Jeannette Green, Glenn S. Kroog
| Nature Verified
Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR).
Open in Who Shared Issue with article?
See all 2 articles